Acasă › Cancer de sân triplu negativ › Texas › Houston
Studii clinice pentru Cancer de sân triplu negativ în Houston, TX
42 studii pentru Cancer de sân triplu negativ caută participanți în și în jurul orașului Houston (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
În curs de recrutareFaza 1
- University of Texas MD Anderson Cancer Center, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
În curs de recrutareFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
În curs de recrutareFaza 1/2
- MD Anderson Cancer Center, Houston
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
În curs de recrutareFaza 1/2
- MD Anderson Cancer Center, Houston
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
În curs de recrutare
- M D Anderson Cancer Center, Houston
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
În curs de recrutareFaza 3
- Kelsey-Seybold Clinic - North Houston Campus ( Site 0096), Houston
- Kelsey-Seybold Clinic ( Site 0040), Houston
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
În curs de recrutareFaza 3
- Oncology Consultants P.A. ( Site 0107), Houston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
În curs de recrutareFaza 3
- Kelsey-Seybold Clinic ( Site 0042), Houston
- Kelsey-Seybold Clinic ( Site 0088), Houston
- Oncology Consultants P.A. ( Site 0073), Houston
Intratumoral N17350 in Advanced Solid Tumors
În curs de recrutareFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
În curs de recrutareFaza 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
În curs de recrutareFaza 2
- Baylor College of Medicine, Houston
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
În curs de recrutareFaza 1
- MD Anderson Cancer Center, Houston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
În curs de recrutareFaza 3
- MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
În curs de recrutareFaza 1
- The University of Texas - MD Anderson Cancer Center, Houston
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
În curs de recrutareStudiu observațional
- UT Health Houston, Houston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
În curs de recrutareFaza 1
- MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1/2
- Research Site, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
În curs de recrutareFaza 1
- Normunity Investigational Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Houston Methodist Hospital, Houston
SMP-3124LP in Adults With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- MD Anderson Cancer Center, Houston
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
În curs de recrutareFaza 1
- UT MD Anderson Cancer Center, Houston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
În curs de recrutareFaza 2/3
- (USOR) Texas Oncology, Houston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
În curs de recrutareFaza 1
- Uni Of TX MD Anderson Cancer Cntr, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
În curs de recrutareFaza 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
În curs de recrutareFaza 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
În curs de recrutareFaza 1/2
- MD Anderson, Houston
A Study of LY4175408 in Participants With Advanced Cancer
În curs de recrutareFaza 1
- MD Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
În curs de recrutareFaza 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
Study of XB010 in Subjects With Solid Tumors
În curs de recrutareFaza 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
În curs de recrutareFaza 1
- MD Anderson, Houston
- NEXT Texas LLC - Houston, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
În curs de recrutareFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
În curs de recrutareFaza 2
- Houston Methodist Neal Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
În curs de recrutareFaza 2
- MD Anderson Cancer Center, Houston
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
În curs de recrutareFaza 1
- MD Anderson Cancer Center, Houston
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
În curs de recrutareFaza 1/2
- M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
În curs de recrutareFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
În curs de recrutareFaza 1
- MD Anderson Cancer Center, Houston
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
În curs de recrutareFaza 2
- Harris Health System - Smith Clinic, Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston
CtDNA Based MRD Testing for NAC Monitoring in TNBC
În curs de recrutareStudiu observațional
- The University of Texas MD Anderson Cancer Center, Houston
Studii pentru Cancer de sân triplu negativ în alte orașe
- New York City, NY31 studii
- Nashville, TN28 studii
- Los Angeles, CA27 studii
- Boston, MA26 studii
- San Antonio, TX23 studii
- St. Louis, MO21 studii
- Arlington, VA20 studii
- Atlanta, GA20 studii
- Dallas, TX18 studii
- Chicago, IL16 studii
- Columbus, OH16 studii
- Grand Rapids, MI15 studii
Alte studii în Houston
- Cancer pulmonar cu celule non-pătrate145 studii
- Cancer de sân126 studii
- Cancer (toate tipurile)121 studii
- Cancer metastatic104 studii
- Cancer colorectal102 studii
- Cancer ovarian89 studii
- Leucemie mieloasă acută85 studii
- Cancer pulmonar78 studii
- Cancer de prostată76 studii
- Cancer endometrial68 studii
- Cancer pancreatic61 studii
- Melanom59 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.